Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

Phase 3positiveLivdelziPositive

AI Analysis

Summary

Gilead announced that Livdelzi (Seladelpar) achieved statistically significant composite ALP normalization in the Phase 3 IDEAL trial for primary biliary cholangitis. This positive Phase 3 result supports the drug's clinical efficacy for this indication.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Statistically significant composite ALP normalization achieved in Phase 3 IDEAL Trial

Importance:7/10

Sentiment:

0.85

Phase 3 dataPrimary endpoint metPBCLivdelziSeladelpar

Related Companies

$GILD

Read the original article

Published by yahoo_finance on June 2, 2026 12:30 PM

Read Original